MDACC Study No:2013-0907 ( NCT No: NCT02029443)
Title:A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia
Principal Investigator:Susan O'Brien
Treatment Agent:ACP-196
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of ACP-196 that can be given to patients with CLL. The safety of ACP-196 will
also be studied, and whether it can help to control the disease. This is the
first study using ACP-196 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:ACP-196
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Acerta Pharma BV
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Susan O'Brien
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults